TICKERNERD
Menu
INGNHealthcare · Medical Devices

INGN Stock Forecast: Inogen, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$5.61
+0.18% on the day

The 3 Wall Street analysts covering Inogen, Inc. hold a median 12-month price target of $12 — +113.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 86 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$148.9M
Ticker Nerd rank
86 / 100
Median analyst target
$12
Analysts covering
3
Total return, dividends reinvested
1W
−2.4%
1M
−12.8%
YTD
−16.5%
1Y
−25.5%
From 52W high
−37.3%
From 52W low
+0.4%
$5.59
$8.95
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

INGN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Inogen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
86 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
88
Accruals
85
Issuance
80
Size
71
Volatility
66
Value
64
Revisions
51
Growth
49
Momentum
46

Quality (88): The business earns solid, repeatable profits on what it owns.

Momentum (46): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

INGN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on INGN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$6.00$8.00$10.00$12.00$14.00Oct 25Jan 26Apr 26Jul 26INGNHigh $14Median $12Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $12Median $12High $14

The green dot is the last close — the median target sits +113.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 Apr 2026Freedom BrokerInitiatesBuy$12
16 June 2025B. Riley SecuritiesInitiatesBuy—
22 May 2025NeedhamUpgradeBuy—
8 May 2025StifelMaintainsHold—
9 Apr 2025NeedhamReiteratesHold—
27 Feb 2025NeedhamReiteratesHold—
26 Feb 2025NeedhamReiteratesHold—
30 Jan 2025NeedhamReiteratesHold—
14 Jan 2025NeedhamReiteratesHold—
8 Nov 2024NeedhamReiteratesHold—
7 Aug 2024NeedhamReiteratesHold—
8 May 2024NeedhamReiteratesHold—
8 May 2024StifelMaintainsHold—
9 Apr 2024NeedhamReiteratesHold—
15 Feb 2024William BlairUpgradeOutperform—
8 Nov 2023JP MorganMaintainsUnderweight—
8 Aug 2023JP MorganDowngradeUnderweight—
8 Aug 2023StifelMaintainsHold—
14 July 2023NeedhamDowngradeHold—
20 Apr 2023NeedhamReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INGN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

INGN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Inogen, Inc. (INGN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−6.5×

Cheaper than 91% of US stocks

Price / sales
0.4×

Cheaper than 85% of US stocks

Price / book
0.9×

Cheaper than 78% of US stocks

EV / EBITDA
−7.3×

Cheaper than 81% of US stocks

Growth & margins
Revenue growth (YoY)
3.0%

Higher than 34% of US stocks

Earnings growth (YoY)
3.0%

Higher than 39% of US stocks

Gross margin
45.5%

Higher than 57% of US stocks

Operating margin
−5.1%

Higher than 27% of US stocks

Net margin
−6.9%

Higher than 22% of US stocks

Returns & dividend
Return on equity
−13.1%

Higher than 34% of US stocks

Return on assets
−5.8%

Higher than 30% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

INGN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
INGNInogen, Inc.$148.9M
86
OWLTOwlet, Inc.$150.8M
34
MXCTMaxCyte, Inc.$147.8M
72
QTRXQuanterix Corp.$140.8M
28
QSIQuantum-Si, Inc.$179.9M
31
APYXApyx Medical Corp.$128.0M
70
LUCDLucid Diagnostics, Inc.$195.8M
45

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Inogen, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest INGN news & analysis

Here's Why You Should Retain Inogen Stock in Your Portfolio for Now

Zacks Investment Research · 21 Aug 2026neutral

A Zacks Investment Research article discusses why investors should retain Inogen stock, citing portable oxygen concentrator (POC) demand, new products, and international growth as supporting its outlook, while noting U.S. channel shifts and distributor timing as risks.

Why it matters — A Inogen watcher would care because the article highlights the balance of growth drivers and specific risks that could shape the company's near-term performance.

Should Investors Buy Inogen as Low Valuation Meets Execution Risk?

Zacks Investment Research · 11 Aug 2026neutral

Zacks Investment Research notes that Inogen's low valuation and improving margins are offset by weak U.S. sales and rental performance despite strong international demand.

Why it matters — For INGN watchers, the piece highlights the ongoing tension between the company's discounted valuation and the risks posed by its domestic sales challenges.

Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists

Zacks Investment Research · 11 Aug 2026negative

Inogen lowered its 2026 revenue outlook, citing ongoing pressure in the U.S. channel. The company is relying on international growth, new products, and cost control to provide support.

Why it matters — INGN watchers would care because the reduced guidance signals weaker near-term U.S. demand expectations that could weigh on the company's performance.

Inogen Q2 Earnings Beat Estimates, Sales Rise Y/Y, 2026 View Cut

Zacks Investment Research · 10 Aug 2026neutral

Inogen reported Q2 earnings that beat expectations, with total revenues up 3% year-over-year driven by a 14.8% increase in international sales, though the company cut its 2026 revenue outlook due to weakness in the U.S. market.

Why it matters — INGN investors would note the mixed signals of an earnings beat and international growth offset by a lowered 2026 outlook tied to ongoing U.S. market struggles.

Inogen, Inc. (INGN) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Inogen, Inc. held its Q2 2026 earnings call, and Seeking Alpha published the full transcript of the call. The transcript records the company's second-quarter 2026 earnings discussion with investors and analysts.

Why it matters — An INGN watcher would use the transcript to hear management's own account of the company's quarterly results and outlook directly from the earnings call.

FAQ

Frequently asked questions about INGN stock

What is the INGN stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Inogen, Inc. have a median 12-month price target of $12, with estimates ranging from $12 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is INGN stock a buy right now?

Of the 3 analysts covering Inogen, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Inogen, Inc. 86 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank INGN?

As at 22 Aug 2026, Inogen, Inc. ranks 86 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (88 of 100).

Will INGN stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +113.9% from the last close, and Ticker Nerd's factor model ranks Inogen, Inc. 86 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the INGN stock forecast for 2030?

No analyst covering Inogen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $14 over the next 12 months.

How has INGN stock performed over the past year?

Inogen, Inc. returned -25.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Inogen, Inc. do?

Inogen Inc. is a medical technology company that specializes in innovative respiratory products designed to improve the quality of life for patients with chronic respiratory conditions.

What is the latest news on INGN?

The most recent item we track (Zacks Investment Research, 21 Aug 2026): "Here's Why You Should Retain Inogen Stock in Your Portfolio for Now". A Zacks Investment Research article discusses why investors should retain Inogen stock, citing portable oxygen concentrator (POC) demand, new products, and international growth as supporting its outlook, while noting U.S. channel shifts and distributor timing as risks.

Company

About Inogen, Inc.

Inogen Inc. is a medical technology company that specializes in innovative respiratory products designed to improve the quality of life for patients with chronic respiratory conditions. Notably, Inogen focuses on developing portable oxygen concentrators, which offer users greater mobility and independence compared to traditional oxygen tanks. These devices are particularly impactful in the healthcare sector, providing respiratory patients with an effective, convenient solution for supplementing oxygen therapy. Inogen's products are utilized by both patients and healthcare providers, addressing the needs of diverse settings, including home care and medical institutions. The company's commitment to research and development underscores its dedication to advancing respiratory care technology. Headquartered in Goleta, California, Inogen collaborates with distributors and resellers globally, enhancing its market reach and significance. In the broader financial market context, Inogen plays a crucial role in the healthcare technology sector, contributing to advancements in patient care and supporting a more dynamic and innovative approach to medical treatment for chronic illnesses. Established in 2001, the company continues to expand its footprint as a leader in portable oxygen solutions.

CEO Mr. Kevin R. M. Smith · 753 employees · United States · https://www.provider.inogen.com